Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Small Cell Lung Carcinoma 8Lung Neoplasms 4Sarcoma, Ewing 2Sarcoma 2SCLC, Extensive Stage 1Recurrence 1Platinum-Resistant Lung Small Cell Carcinoma 1Ovarian Neoplasms 1Neutropenia 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Gastrointestinal Malignancies 1Endometrial Neoplasms 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 22Cisplatin 20Nivolumab 8Gemcitabine 7Carboplatin 7durvalumab 5Ipilimumab 5Bevacizumab 5pembrolizumab 4Radiotherapy, Intensity-Modulated 4tremelimumab 3niraparib 3Oxaliplatin 3Drug Therapy 3Cyclophosphamide 3Cerebral Decortication 3Blood Specimen Collection 3sargramostim 2Thoracoscopy 2Surveys and Questionnaires 2Sorafenib 2Radiosurgery 2Magnesium Sulfate 2Leucovorin 2Imatinib Mesylate 2Hyperthermic Intraperitoneal Chemotherapy 2Doxorubicin 2Dexamethasone 2tislelizumab 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Mesothelioma × PM 01183 × Clear all
NCT03213301 2021-07-14

Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.

Swiss Cancer Institute

Phase 2 Completed
42 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡